post

Myeloma UK appoints two new trustees to its Board

Myeloma UK is delighted to welcome two new trustees to its Board, who both bring a wealth of relevant experience.

Myeloma UK news // 28th November 2018

Myeloma UK is delighted to welcome two new trustees to its Board, who both bring a wealth of relevant experience.

Dr Karthik Ramasamy is a consultant haematologist at Oxford University Hospitals NHS Trust and the Director of the Oxford Myeloma Translational Research Centre. He is also Lead Clinician for myeloma and other plasma cell dyscrasias at the Thames Valley Strategic Clinical Network. He has been a Chief Investigator of myeloma studies in renal impairment and bone disease and Principal Investigator on several myeloma trials.

Dr Ramasamy said “I am excited at the opportunity of joining the Myeloma UK Board. In my opinion, Myeloma UK has been a beacon for all cancer charities by championing for both excellence in clinical care for patients and through its funding of patient centred research. Myeloma UK is highly valued by patients, carers and health care professionals alike and as myeloma treatment pathways are undergoing major transformation, as a clinician I hope to add value to the Board in this area.”

 

Geraldine Haley has spent 25 years with Standard Chartered Bank, where she gained generalist and specialist Human Resources experience, including time as Global Head of HR for Corporate and Institutional Banking and culminating in her role as Global Head of Executive Talent.  Geraldine set-up a consulting practice in 2016 where she focuses on coaching Senior Executives, accelerating team performance and bespoke leadership development programmes.

Geraldine said “It is a privilege to join the Board and I hope to provide a carer’s perspective, as my husband has multiple myeloma, along with my business psychology and organisation development experience.”

“We are truly delighted to have appointed two outstanding trustees who each bring with them rich and applicable knowledge in areas that will contribute greatly to our Board.”

Judy Dewinter, Chairman of the Myeloma UK Board